Drug Profile
Research programme: cancer and immunology therapeutics - PhoreMost/The Wistar Institute
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator University of Cambridge; Wistar Institute
- Developer Wistar Institute
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Immunological disorders
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Apr 2020 No recent reports of development identified for research development in Cancer in USA
- 28 Apr 2020 No recent reports of development identified for research development in Immunological-disorders in United Kingdom